Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$92.49 +3.81%

+$3.89 today

Market cap
$6.04B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.50M

Average 0.95M

MIRM Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue growth accelerates

Q2 FY2026 cost of revenue of $30.35M rose 29.6% year over year, ahead of the +25.6% change in trailing-twelve-month cost of revenue. Sequentially, it rose 5.1% from the prior quarter. Over 3 fiscal years it compounded at +101.1% a year.

Context

  • Cost of revenue amounted to 19.3% of revenue in FY2025, down 4.9 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +29.6% holds above the trailing-twelve-month pace of +25.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$30.35M+5.1% QoQ
Last fiscal yearDec 2025
$100.58M+23.2% YoY
LTMJun 2026
$113.1M+25.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.6%——
1 year+23.2%——
3-year CAGR+101.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
100.58M USD
Year-over-year change
+23.2%
4-year CAGR
+169.6%

Cost of Revenue vs competitors

How MIRM compares with its peers on the latest reported figures

  • MIRM's LTM Jun 2026 cost of revenue of $113.1M is the highest of the 8 companies compared; the peer median is $14.98M.
  • Its year-over-year change of +25.6% is the 4th highest of 5, against a peer median of +131.3%.
  • Cost of revenue amounts to 18.3% of revenue for MIRM, versus a peer median of 8.8%.
MIRM Competitors Peer median
Cost of Revenue for MIRM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$113.1M +25.6%+101.1%18.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$109.99M +25.2%+56.7%16.4%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$109.42M +470.7%—8.5%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$31.49M +204.6%+32.7%4.8%
ALTAltimmune, Inc.LTM Mar 2026$14.98M ——41619.4%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$11.84M +58.0%+89.1%17.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M ——8.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$1.21M ——1.7%
Peer median (excluding MIRM) $14.98M+131.3%+56.7%8.8%

Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.14M77.06M186.37M336.89M521.31M
Cost of Revenue1.9M12.37M47.04M81.64M100.58M
Gross Profit17.24M64.69M139.34M255.25M420.73M
Gross Margin90.1%83.9%74.8%75.8%80.7%
Research & Development131.43M106.84M102.61M140.63M186.18M
Selling, General & Admin59.22M89.07M145.88M202.22M257.03M
Operating Expenses190.65M195.91M248.49M342.85M443.21M
Depreciation & Amortization975K3.24M10.83M23.63M24.24M
EBITDA(65.39M)(122.85M)(136.49M)(48.97M)17.21M
EBITDA Margin-341.7%-159.4%-73.2%-14.5%3.3%
Operating Income(173.41M)(131.22M)(109.15M)(87.61M)(22.14M)
Operating Margin-906.1%-170.3%-58.6%-26.0%-4.2%
Interest Income366K3.86M13.74M13.79M12.73M
Interest Expense17.59M15.98M15.11M14.31M14.39M
Other Income / Expenses89.46M(10.85M)(53.27M)694K709K
Income Before Tax(83.95M)(142.07M)(162.42M)(86.91M)(21.43M)
Pre-Tax Margin-438.7%-184.4%-87.1%-25.8%-4.1%
Income Tax Expense37K(6.41M)991K1.03M1.94M
Net Income(83.99M)(135.67M)(163.42M)(87.94M)(23.36M)
Net Margin-438.9%-176.0%-87.7%-26.1%-4.5%
EPS (Basic)(2.77)(4.01)(4.00)(1.85)(0.47)
EPS (Diluted)(2.77)(4.02)(4.00)(1.85)(0.47)
Weighted Avg Shares30.32M33.84M40.89M47.52M50.2M
Weighted Avg Shares (Diluted)30.32M33.98M40.89M47.52M50.2M

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Intrinsic Alpha fair value

Locked

Current Price

$92.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.